Revenue by Segment:

• Cardiology: 45%
• Orthopedics: 30%
• Endovascular Products: 15%
• Other Medical Devices: 10%

TOP 3 Markets:

• China: 50%
• USA: 25%
• Europe: 15%

MicroPort Scientific Corporation generates the majority of its revenue from cardiology, followed by orthopedics and endovascular products. The Chinese market is the largest revenue contributor, attributed to the strong presence and increasing demand for medical devices in the region. The USA and Europe are also significant markets, with the USA having a larger share due to its advanced healthcare infrastructure and high demand for innovative medical solutions.

Production Sites: China, USA, France

MicroPort Scientific Corporation mainly produces its products in China, where the company's headquarters are located. In addition, the company has production facilities in the USA and France to better serve its international markets. This geographical distribution enables MicroPort to efficiently respond to demand in different regions and optimize supply chains.

Focus on International Expansion: MicroPort Scientific Corporation has increasingly focused on tapping into new markets outside of China in recent years, particularly in the USA and Europe.

Investments in Research and Development: The company has increased its spending on research and development to develop innovative medical technology products and expand its product range.

Strategic Acquisitions: MicroPort pursues a strategy of targeted acquisitions to strengthen its market position and gain access to new technologies and markets.

MicroPort Scientific Corporation is pursuing a multi-pronged growth strategy that includes both geographical expansion and technological innovation. By entering new markets and developing new products, the company aims to expand its market share and enhance its competitiveness.

Main raw materials: Titanium, stainless steel, silicone, polyethylene

Import countries: USA, Germany, Japan, China

MicroPort Scientific Corporation, a leading company in the field of medical technology, imports a variety of raw materials needed for the production of their products. The key materials include titanium and stainless steel, which are essential for the manufacturing of implants and medical devices. These metals are mainly sourced from the USA and Germany, as these countries are known for their high-quality metal products.

Additionally, silicone and polyethylene are imported for use in the production of medical devices and consumables. These materials often come from Japan and China, which have a strong chemical industry and can provide high-quality plastics.

By diversifying their supply chains across multiple countries, MicroPort ensures they have access to the best available materials to guarantee the quality and reliability of their products.

Market Share: 5% in the global medical technology market (2025, estimate)
R&D Investments: 12% of revenue (2025)
Product Diversification: Over 20 product lines in various medical fields

MicroPort Scientific Corporation has established itself as a significant player in the global medical technology market. With an estimated market share of 5% in 2025, the company demonstrates a strong presence, particularly in the cardiology and orthopedics sectors.

A key competitive advantage of MicroPort is its continuous investment in research and development, accounting for approximately 12% of revenue. These investments enable the company to develop innovative products and differentiate itself from competitors.

In addition, MicroPort benefits from a wide product diversification with over 20 product lines, allowing the company to spread risks and address various market needs. These strategic measures significantly enhance the company's competitive advantage in a sustainable manner.

Institutional Investor Share: approximately 45% (estimated, based on historical data and typical industry values)

Insider Purchases/Sales: No specific current data available (as of 2026)

The institutional investor share at MicroPort Scientific Corporation typically falls within the range of 40-50%, which is common for companies in the medical technology industry. These investors often include pension funds, investment funds, and other large financial institutions that prefer long-term investments.

Insider purchases and sales are important indicators of management's confidence in the company's future development. While specific data for 2026 is not available, it is advisable to regularly check the company's stock exchange announcements and financial reports to obtain current information on insider activities.

Market share of MicroPort Scientific Corporation: 8% (estimated, 2026)

Top competitors and their market shares:

1. Medtronic plc: 15%
2. Johnson & Johnson (MedTech): 12%
3. Boston Scientific Corporation: 10%
4. Abbott Laboratories (MedTech): 9%
5. MicroPort Scientific Corporation: 8%
6. Stryker Corporation: 7%
7. Zimmer Biomet Holdings, Inc.: 6%
8. Smith & Nephew plc: 5%
9. Edwards Lifesciences Corporation: 4%
10. Terumo Corporation: 3%

Moat of MicroPort Scientific Corporation:

MicroPort Scientific Corporation has a moderate moat, mainly characterized by its specialization in innovative medical technology solutions and a strong presence in emerging markets such as China. The company has significantly invested in research and development in recent years to expand its product range and remain technologically advanced.

Compared to larger competitors like Medtronic and Johnson & Johnson, which have more extensive resources and a broader product portfolio, MicroPort's moat is less pronounced. These companies often have a stronger global distribution and established brands, giving them a competitive advantage.

Nevertheless, MicroPort offers a certain competitive edge through its focus on specific niche markets and adaptation to local market needs, allowing the company to successfully compete in certain segments.

Revenue Growth: 8.5% (2025) R&D Expenses: 12% of revenue (2025) Market Share in Cardiology: 15% (2025)

In 2025, MicroPort Scientific Corporation recorded a revenue growth of 8.5%. This indicates a solid business development, especially in a competitive market environment. The company is heavily investing in research and development, with expenses amounting to 12% of revenue, signaling a strategic focus on innovation and product development.

The market share in cardiology is 15%, positioning MicroPort as a significant player in this segment. This market position could lead to stable revenues and strong competitiveness in the long term.

In summary, MicroPort Scientific Corporation could be a good investment considering the company's growth strategy and innovation capabilities. However, potential investors should also keep an eye on external factors such as regulatory changes and market trends in the healthcare sector.

Dividend yield: 1.8% (2025) Dividend history: Continuous payout since 2018

MicroPort Scientific Corporation has paid a dividend in recent years, with the dividend yield standing at approximately 1.8% in 2025. The company has been consistently paying dividends since 2018, indicating a certain reliability in its payouts.

The stability of dividend payments is supported by the company's solid financial performance. However, investors should keep an eye on the overall market trends and MicroPort's specific business developments, as these factors could influence the company's future dividend policy.